

Index

- A1C, S5, S8, S11, S12, S20, **S21–S22**, S97–S99
 advantages of, S21
 age and, S21–S22
 cardiovascular disease and, S102–S103
 CGM technology effect on, S106, S112, S115–S116
 confirming diagnosis with, S22
 correlation with BGM, S98
 hemoglobinopathies and, **S22**
 in children, S98–S99, S235–S237, S241–S242
 in hospitalized patients, S268
 in older adults, S219, S220, S223
 in people with HIV, **S28**
 in screening children, **S28**
 limitations, **S98**
 microvascular complications and, S101–S102
 other conditions affecting, **S22**
 point-of-care assays, S5, S21, S98
 in prediabetes, S24–S25
 in pregnancy, S256, **S257–S258**
 race/ethnicity and, **S22**, S98–S99
 recommendations, **S21**
 setting and modifying goals for, S103–S104
- acarbose, S136, S152
 access to care, S13
 access, to insulin, S279
 ACCORD study, S57, S170, S218
 ACE inhibitors, S53, S54, S163, S164–S165, S192, S194, S196, S238, S239, S244, S255, S261
 acute kidney injury, S134, S161, S162, **S165**, S177, **S194**, S272
 ADA consensus reports, S4, S70, S78, S106, S217
 ADA evidence-grading system, S3
 ADA Professional Practice Committee, S1, S4
 ADA scientific reviews, S4
 ADA statements, S4
 ADAG study, S98, S104, S105
 Addison disease, S23, S56, S237
 adolescents. *see* children and adolescents.
 adrenal insufficiency, primary, S56, S237
 adult-onset diabetes. *see* Type 2 diabetes.
 adults, prediabetes and diabetes screening in, S25, S27–S28
 ADVANCE trial, S103, S105, S160
 advocacy statements, S7, **S279–S280**
 care of young children with diabetes in the childcare setting, S280
 diabetes and driving, S280
 diabetes and employment, S280
 diabetes care in the school setting, S279–S280
 insulin access and affordability, S279
- affordability, of insulin, S279
 Affordable Care Act, S13
 African Americans, S22, S23, S24, S25, S27, S77, S105, S193
 A1C variability in, S98–S99
 ADA risk test for, S26
 BMI cut point in, S28
- age
 aspirin use and, S171
 effect on A1C, **S21–S22**
 to start screening for diabetes, S24, S27
 risk factor for diabetes, **S27**
 statin treatment and, S167
- agricultural workers, migrant, S13
 AIM-HIGH trial, S170
 albiglutide, S181, S182
 albuminuria, S7, S75, S79, S105, S148, S159, S161, S164, S165, S171, S176, S182, S183, S191, S192, **S193**, S194, S195, S196, S197, S198, S199, S237, S239, S240
 alcohol intake, S54, S57, S72, **S76**, S106, S117, S136, S163, S169, S207, S246, S255
 algorithms, insulin dosing, using machine learning, S9, S268
 alirocumab, S168
 alogliptin, S148, S152, S173, S183, S270
 alpha-glucosidase inhibitors, S44, S131, S152
 alpha-lipoic acid, **S208**
 ambulatory glucose profile (AGP), S100
 amputation, foot, S177, S206, S209, S210, S211, S212
 analogs. *see* insulin analogs.
 angiotensin receptor blockers (ARBs), S7, S53, S54, S147, S163, S164–S165, S191–S192, S194, S231, S238
 anti-VEGF agents, **S205–S206**
 antiplatelet agents, **S170–S172**
 antipsychotics, atypical, S26, S28, S84
 antiretroviral therapies, S24, S28
 anxiety disorders, S82, S136
 ARRIVE trial, S171
 ASCEND trial, S75, S171, S172
 Asian Americans, S23, S24, S25, S26, S27, S28, S43, S129, S130, S132, S135
 aspart, S29, S141, S153, S222
 aspirin therapy, S170, **S171–S172**, S205, S219
 ASPREE trial, S171
 atenolol, S208, S261
 atherosclerotic cardiovascular disease (ASCVD), **S158–S190**
 atorvastatin, S167
 atypical antipsychotics, S26, S28, S84
 autoimmune diseases, S23, **S57**, **S237**
 automated insulin delivery (AID) systems, S6–S7, S111, S112, S115, **S118–S119**, S141
 autonomic neuropathy, diabetic, S8, **S78**, S160, S206, **S207**, S273
- balloons, implanted gastric, S132
 bariatric surgery. *see* metabolic surgery.
 basal insulin, S9, **S113–S114**, S116, S119, S140, S141, S150, **S151**, S152, S153, S154–S145, S222, S224, S226, S233, S269, S270, S271, S272, S273
 bedtime dosing
 of antihypertensives, S165
 of insulin, S144–S145, S150, S220, S222, S235
 behavior changes, S6, S12, **S68–S96**
 diabetes self-management education and support, **S68–S70**
 for diabetes prevention, **S42–S43**
 medical nutrition therapy, **S68–S76**
 physical activity, **S76–S78**
 in gestational diabetes, **S258**
 psychosocial care, **S79–S86**
 smoking cessation, **S79**
 for weight loss, S130–S131
- bempedoic acid, **S169**
 beta-carotene, S6, S72, S76
 beta-cell replacement therapy, S142, S146
 biguanides, S152
 bladder dysfunction, S207, S256
 Blood Glucose Awareness Training, S82, S106
 blood glucose monitoring (BGM), S50, S75, S79, S97, S104, **S111–S114**, S144–S145, S243
 in hospitalized patients, **S269**
 continuous glucose monitoring, **S99–S101**
 correlation with A1C, S98
 devices for, **S111–S127**
 during pregnancy, S257
 in hypoglycemia, S104, S106
 in intensive insulin regimens, **S113**
 in people on basal insulin, oral agents, or noninsulin injectables, **S113–S114**
 in schools, S112
 initiation of, S112
 meter standards, **S113**
 optimizing, **S113–S114**
 blood pressure control. *see also* hypertension, S8, **S159–S165**, S191, S195, **S208**, S224, S225
 body mass index (BMI), S9, S24–S25, S43, S44, S45, S53, S76
 COVID-19 mortality and, S60
 effects of metformin use in pregnancy on, S259
 ethnicity and, **S27–S28**
 for medical weight loss medications, S132
 for metabolic surgery, S132, S135, S243, S244
 in obese patients, S129–S130
 in screening children, S240–S241
 postpartum, S262
 bone fracture risk, S44, S45, S60, S148
 bone-strengthening activities, S76, S77, S233, S241, S242
 bromocriptine, S152
- calcium channel blockers, S164, S165, S196
 canagliflozin, S151, S152, S177, S178, S179, S181, S182, S183, S197
 cancer, risk in diabetics, **S56–S57**
 CANVAS study, S177, S178, S179, S182, S197, S199
 capsaicin, topical, **S208**
 carbamazepine, **S208**
 carbohydrate intake, S14, S21, S24, S42, S72, **S73–S75**, S78, S104, S136, S140, S142, S144–S145, S225, S233–S234, S257, S258, S259, S271, S272
 cardiac autonomic neuropathy, diabetic, S206, **S207**
 cardiac function testing, **S245–S246**
 cardiovascular disease, S2, S7, **S158–S190**
 A1C and outcomes of, S102–S103
 antiplatelet agents, **S170–S172**
 cardiac testing, **S176**
 hypertension/blood pressure control, **S159–S165**
 lifestyle and pharmacologic interventions, **S176–S184**

- lipid management, **S165–S166**
prevention of, **S44–S45**, S224
screening, S172, **S176**
statin treatment, **S165–S170**
treatment, **S172–S176**
- cardiovascular risk, S13, S15, S25, S27, S31, S44, S45, S76, S78, S101, S102, S129, S135, S143, S158, S159, S160, S162, S166, S167, S169, S172, S176, S180, S184, S193, S194, S195, S197, S207, S218–S219, S238
risk calculator, **S159**
- care delivery systems, S11–S13
access to care and quality improvement, S13
behaviors and well-being, S12
care teams, S12
chronic care model, S11
medication cost considerations, S12
six core elements, S11
system-level improvement strategies, S11–S12
telehealth, S12
- care teams, S12
- CARMELINA trial, S173, S182
- CAROLINA trial, S173, S177
- celiac disease, S23, S56, S231, **S237–S238**
- CHAP trial, S7, S9, S164, S261
- Charcot neuropathy, S78, S209, S211
- childcare, S233, S279, S280
- children and adolescents, S7, S8, **S230–S253**, S279–S280
A1C in, S98–S99, S235–S237, S241–S242
asymptomatic, risk-based screening in, S25
cystic fibrosis-related diabetes in, **S28–S29**
diabetes care in childcare settings, S233, S279, S280
diabetes care in school setting, S112, S234, S279–S280
insulin pumps in, S119
maturity-onset diabetes of the young (MODY), S19, **S28–S29**, S30
monogenic diabetes syndromes, S19, S30–S32
neonatal diabetes, S19, S30, S31
physical activity in, S76, S77
screening for type 1 risk, S24–S25
screening for prediabetes and type 2, S25, S28
transition from pediatric to adult care, **S246**
type 1 diabetes in, **S233–S240**
type 2 diabetes in, **S240–S246**
- China Da Qing Diabetes Prevention Outcome Study, S45
- CHIPS trial, S163, S261
- cholesterol lowering therapy, S7, S53, S166, S167, **S168–S169**
- chronic care model, S11
- chronic kidney disease, diabetic, S8, **S191–S202**
acute kidney injury, **S194**
assessing albuminuria and GFR, **S193**
diagnosis, **S193–S194**
epidemiology, **S193**
interventions for, **S195–S199**
referral to nephrologist, **S199**
risk of progression, S191, S193
screening recommendations, **S191**
staging, S194
surveillance, S194–S195
treatment recommendations, **S191–S183**
- classification, S5, **S19–S20**
- clonidine, S208, S261
- clopidogrel, S170
- closed-loop systems, S105, S119, S144
do-it-yourself, **S120**
hybrid, S141, S218, S234, S260
- coaching, online, S69, S120
- cognitive capacity/impairment, S80, **S84–S86**
- colesevelam, S152
- collaborative care, **S49–S51**
- collagen vascular diseases, S56
- combination therapy, S7, S143, S144, S146, S147, S149, S150–S151, S154, S161, S168, S168–S169, S169–S170, S208, S222
- community health workers, S5, S13, S15, S43, S70, S79
- community screening, **S28**
- community support, S15
- comorbidities, S10, S11, **S56–S60**
assessment of, S6, **S49–S67**
autoimmune diseases, S23, **S57, S237**
cancer, **S56–S57**
cognitive impairment/dementia, **S57**
COVID-19, **S60–S62**
fractures, S148, S161, S177, S222, S223
nonalcoholic fatty liver disease, **S57–S60**
obstructive sleep apnea, **S60**
periodontal disease, **S60**
prevention or delay of, S5, **S41–S48**
- COMPASS trial, S172, S283
- computerized prescriber order entry (CPOE), S9, S267, S268
- CONCEPT study, S257, S258
- connected insulin pens, S112, S117–S118, S236
- continuous glucose monitoring (CGM), S6, S7, S8, S9, S50, **S114–S117**
ambulatory glucose profile in, S99, S100, S101
assessment of glycemic control, S97, S98, S99–S101
devices for, **S114–S117**
in hospitalized patients, S269, S271, S272
in hypoglycemia prevention, S106
in older adults, S218
in pediatric type 1 diabetes, S99, S112, S234, S236
in pediatric type 2 diabetes, S243
in pregnancy, S116, S258
interfering substances, S117
intermittently scanned devices, S106, S114–S115, S116, S235, S236, S241, S258
side effects, S116–S117
standardized metrics for, S99
- continuous subcutaneous insulin infusion (CSII), S140–S141
- coronary artery disease, S78, S164, S165, S172, S176
- cost considerations, S11, **S12**, S13
glycemic control, S9, S148, S221, S222
insulin therapy, S117, S119, S141, S150, S151, S153, S260, S279
metabolic surgery, S135
weight loss medications, S132–S134, S151
- Counterfeit test strips, S113
- COVID-19, S7, **S60–S62**, S129, S269
- COVID-19 vaccines, S6, S51, **S56**
- CREDESCENCE study, S177, S178, S179, S182, S197, S198
- cystic fibrosis-related diabetes, S19, **S28–S29**
- DAPA-CKD study, S177, S178, S179, S197, S198
- DAPA-HF study, S178, S179, S180, S182
- dapagliflozin, S62, S151, S152, S177, S178, S180, S181, S182, S183, S197
- DARE-19 study, S62
- DASH diet, S42, S163, S166
- DECLARE-TIMI 58 study, S177, S178, S179, S182, S197, S198
- degludec, S141, S151, S152, S153, S154, S222
- delay, of type 2 diabetes, S5–S6, **S41–S48**
lifestyle behavior change, **S42–S43**
person-centered care goals, **S45–S46**
pharmacologic interventions, **S43–S44**
recommendations, S41, S42, S43–S44
of vascular disease and mortality, **S44–S45**
- DELIVER study, S178, S179, S180, S182
- dementia, in diabetics, S57, S84, S105, S170, S217–S218
- dental practices, screening in, S28
- depression, S14, S53, S80, S81, **S82–S83**, S119, S133, S136, S208, S216, S217, S220, S223, S235, S246
- detemir, S144, S151, S153, S222
- devices. *see* technology.
- Diabetes Control and Complications Trial (DCCT), S21, S101, S102, S103, S104, S119, S140, S141, S236, S240
- Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), S8, S102, S103, S105, S218
- diabetes distress, S6, S14, S80, **S81–S82**, S83, S115, S235, S246, S274
- diabetes medical management plan (DMMP), for students, S112
- Diabetes Prevention Impact Tool Kit, S43
- Diabetes Prevention Program (DPP), S25, S27, **S42**, S43, S44, S75, S120, S149
delivery and dissemination of, S43
- Diabetes Prevention Recognition Program (DPRP), S43
- diabetes self-management education and support (DSMES), S6, S7, S12, S15, S50, **S68–S70**, S71, S82, S150
- diabetes technology. *see* technology, diabetes.
- diabetic ketoacidosis, S20, S60, S61, S77, S81, S106, S116, S141, S142, S148, S177, S224, S233, S243, S256, S260, **S273**
- diabetic kidney disease. *see also* chronic kidney disease.
dietary protein and, S75
diagnosis, S193–S194
exercise and, S79
finerenone in, S183–S184, S198–S199
glucose-lowering medications for, S196–S198
multiple drug therapy, S165
- Diabetic Retinopathy Study (DRS), S206
- diagnosis, S5, S6, **S19–S35**
confirmation of, S23
criteria for, S21
cystic fibrosis-related, S28–S29
diabetic kidney disease, S193–S194
diabetic neuropathy, S206–S207
diagnostic tests, S20–S22
gestational diabetes mellitus, S33–S35
monogenic diabetes syndromes, S30–S33
pancreatic, S33
posttransplantation, S30–S31
prediabetes, S25
type 1 diabetes, S22–S25

- type 1 vs type 2 in pediatric patients, S242
type 2 diabetes, S25–S28
- diagnostic tests, S20–S22
A1C, S21–S22
age, S21–S22
confirmation of, S22
criteria for, S21
ethnicity, S22
fasting and 2-hr plasma glucose, S21
hemoglobinopathies, S22
race, S22
- diet, *see* Medical nutrition therapy.
- Dietary Reference Intakes, S259
- DIAMOND trial, S8, S218
- digital health technology, **S120**
- dipeptidyl peptidase 4 (DPP4) inhibitors, S30, S131, S147, S148, S149, S152, S173, S177, S222, S270
- disordered eating behavior, S53, S71, S80, S81, **S83–S84**, S233, S234–S235, S246
- do-it-yourself systems, **S120**
- domperidone, S209
- Dose Adjusted for Normal Eating (DAFNE), S106
- DRCR Retina Network, S205
- driving, and diabetes, S280
- droxidopa, S208
- dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, S7, S44, S60, S131, S146, S152
- DUAL-VIII trial, S154
- dulaglutide, S146, S148, S151, S152, S174, S181, S182
- duloxetine, S208
- dyslipidemia, S12, S25, S27, S44, S45, S53, S77, S132, S158, S159, S169, S171, S203, S206, S207, S220, S231, S232, **S238**, S239, S243, **S245**
- e-cigarettes, S239, S246, **S79**
- eating disorders, S71, **S83–S84**, S235
- eating patterns, S6, S42, S50, S59, S71, S72, **S73**, S74, S75, S81
disrupted, S83, S84
- education, *see also* diabetes self-management
education and support (DSMES).
on device use, **S112**
patient, **S210–S211**
preconception, S255, S256
staff, in rehabilitation and LTC settings, S224–S225
- electrical stimulation, gastric, S209, S212
- ELIXA trial, S174, S175, S181
- EMPA-REG OUTCOME trial, S177, S178, S179, S182, S197
- empagliflozin, S151, S152, S177, S178, S179, S180, S181, S182, S183, S189
- EMPEROR-Preserved trial, S180, S182
- EMPEROR-Reduced trial, S180, S182
- employment, diabetes and, S280
- enalapril, S208
- end-of-life care, **S219**, S223, **S225–S226**
- enteral/parenteral feedings, S270, S271, **S272**
- erectile dysfunction, S207, **S209**
- ertugliflozin, S152, S178, S180, S181, S270
- erythromycin, S209
- erythropoietin therapy, A1C and, S21, S22, S219
- estimated average glucose (eAG), S98
- ETDRS study, S205
- Ethnicity, S24, S25, **S27–S28**, S61, S118, S131
effect on A1C, S22
- evidence-grading system, S3
- evolocumab, S168
- EXAMINE trial, S173, S182
- exenatide, S148, S148, S152, S174, S181, S182, S243
- exercise. *see* physical activity.
- exocrine pancreas diseases, S19, **S32**
- EXSCCEL trial, S174, S175, S181
- eye exam, comprehensive, S204, S240
- ezetimibe, S7, S166, S167, S168, S178
statins and, **S168**, S170
- family history, S23, S25, S27, S29, S30, S32, S57, S83, S159, S171, S240, S242
- fasting plasma glucose (FPG) test, S20, S21, S22, S25, S28, S150
- fats, dietary, S9, S72, **S75**, S136, S238, S245, S257, S259
- FDA standards, for glucose meters, S113
- fenofibrate, S169, S170, S206
- fibrate, S232, S245
plus statin therapy, S169, **S170**
- fibrosis-4 index risk calculator, S6, S58
- FIDELIO-DKD trial, S183, S198
- FIGARO-DKD trial, S183, S198, S199
- finerenone, S7, S176, **S183**, S198–S199
- FLOW trial, S197
- fluvastatin, S167
- food insecurity, S13–S14
- foot care, S8, S206, **S209–S212**, S240
- footwear, S78, S209, S211
- FOURIER trial, S168
- fractures, S148, S161, S177, S222, S223
- gastrectomy, vertical sleeve, S135–S136
- gastric aspiration therapy, S132
- gastric bypass, Roux-en-Y gastric, S135–S136
- gastric electrical stimulation, S209
- gastrointestinal neuropathies, **S207**
- gastroparesis, S207, **S208–S209**
- gemfibrozil, S170
- genetic testing, S30–S31, S58
- genitourinary disturbances, **S207**
- gestational diabetes mellitus (GDM), S9, S19, S24, S25, S27, **S32–S35**, S43, S44, S254, **S258–S260**, **S261–S262**
definition, S32–S33
diagnosis, S33–S35
initial testing, S261–S262
insulin, S260
management of, **S258–S260**
medical nutrition therapy, S259
metformin, S259
one-step strategy, S33–S34
pharmacologic therapy, S259
physical activity, S259
postpartum care, S261–S263
recommendations, S32
screening and diagnosis, S33–S35
sulfonylureas, S259
two-step strategy, S34–S35
- glargine, S141, S144, S151, S152, S153, S154, S222
- glimepiride, S148, S152, S173, S177
- glipizide, S148, S152, S222
- glomerular filtration rate, S8, S30, S53, S75, S146, S147, S148, S165, S173, S175, S176, S179, S191–S192, **S193**, S222, S240, S244
- glucagon, S32, S104, **S105–S106**, S150
- glucagon-like peptide 1 receptor agonists (GLP-1 RA), S44, S102, S131, S134, S136, S142, S143, S147, S148, S150, S152, S172, S173, S175, S180, S181, S192, S196, S203, S242, S243, S270
- glucocorticoid therapy, S19, **S272–S273**
- glucose, for hypoglycemia, S104, S105
- glucose meters, S112–S114
counterfeit strips, S113
inaccuracy, S114
interfering substances, S114
optimizing use of, S113–S114
oxygen, S114
standards, S13
temperature, S114
- glucose monitoring. *see* blood glucose monitoring.
- glucose-6-phosphate dehydrogenase deficiency, A1C and, S21, S22, S99
- glucose-lowering therapy, S7
cardiovascular outcomes, S176
choice of, S146
for obesity and weight management, S131
heart failure and, S181–S182
in chronic kidney disease, S196–S198
in hospitalized patients, **S268–S269**
noninsulin, S152
- glulisine, S153, S222
- glyburide, S148, S152, S222, S258, S259
- glycemic control
assessment of, **S98–S101**
physical activity and, S78
- glycemic goals. *see also* glycemic targets, **S101–S104**
- glycemic targets, S6, **S97–S110**
A1c and BGM correlation, S98
A1c and cardiovascular disease outcomes, S102–S103
A1c differences in ethnic groups and children, S98–S99
A1c limitations, S98
continuous glucose monitoring, **S100–S101**
in diabetic kidney disease, S195
goals, **S101–S104**
in hospitalized patients, **S268–S269**
hypoglycemia, **S104–S106**
individualization of, S102, S103
intercurrent illness, **S106**
in older adults, S219–S221
in pediatric type 1 diabetes, S235–S237
in pediatric type 2 diabetes, S241–S242
recommendations, S101
setting and modifying A1C goals, S103–S104
- glycemic treatment, S7, **S140–S157**
- guanfacine, S208
- health literacy, S14–S15
- health numeracy, S12, S14–S15, S49, S50, S71, S75
- hearing impairment, S55
- heart failure, S7, S30, S50, S51, S54, S60, S77, S103, S129, S142, S146, S158–S159, S161, S175, S177, S180–S183
- hemodialysis, A1C and, S21, S219
- hemoglobinopathies, A1C on, S22, S28, S33, S41
- hepatitis B, **S54–S55**, S56
- hepatitis B vaccines, **S54–S55**, S195, S256
- hepatitis C infection, S256
- hepatitis, autoimmune, S23, S56, S237
- homelessness, S13, **S14**, S234, S246
- hospital care, S9, **S267–S278**
care delivery standards, **S267–S268**

- continuous glucose monitoring, **S269**
 diabetes care specialists in, **S268**
 diabetic ketoacidosis, **S273**
 enteral/parenteral feedings, **S272**
 glucocorticoid therapy, **S272–S273**
 glucose-lowering treatment in, **S269–S270**
 glycemic targets in, **S268–S269**
 hyperosmolar hyperglycemic state, **S273**
 hypoglycemia, **S270–S271**
 insulin therapy, **S269–S270**
 medical nutrition therapy in, **S271–S272**
 medication reconciliation, **S274**
 noninsulin therapies, **S270**
 perioperative care, **S273**
 preventing admissions and readmissions, **S274**
 self-management in, **S272**
 standards for special situations, **S272–S273**
 structured discharge communication, **S274**
 transition to ambulatory setting, **S273–S274**
- HOT trial, **S161**
 housing insecurity, **S13, S14**
 HPS2-THRIVE trial, **S170**
 human immunodeficiency virus (HIV), **S19, S21, S22, S24, S28, S207, S256**
 human papilloma virus (HPV) vaccine, **S55**
 human regular insulin, **S151, S152, S153, S272, S273**
 hybrid closed-loop systems, **S119**
 hydrogel, oral, **S132**
 hyperbaric oxygen therapy, **S8, S211, S212**
 hyperglycemia, **S5, S7, S9, S14, S20, S21, S22, S23, S27, S28, S29–S30, S32, S33, S34, S45, S46, S57, S59, S61, S74, S76, S83, S99, S101, S104, S106, S112, S113, S116, S132, S135, S141, S143, S149, S150, S151, S182, S193, S204, S218, S219, S220, S225, S226, S233, S234, S236, S242, S245, S254, S256, S257, S258, S267, S268, S269, S270, S271, S272, S273, S274**
 Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, **S33, S34, S257**
 hyperosmolar hyperglycemic state, **S106, S219, S242, S273**
 hypertension, **S7, S9, S12, S24, S25, S27, S44, S54, S75, S78, S133, S159–S165, S171, S176, S191, S193, S196, S199, S204, S208, S216, S220, S225, S231, S232, S238, S240, S244, S245, S254, S256, S258, S259, S260, S261**
 hypertriglyceridemia, **S75, S140, S149, S169**
 hypoglycemia, **S6, S7, S8, S14, S31, S51, S54, S72, S76, S104–S106**
 CGM technology in prevention of, **S106**
 classification, **S104, S105**
 in hospitalized patients, **S270–S271**
 in older adults, **S57, S217–S218**
 postbariatric, **S132, S136**
 prevention, **S75, S78, S106**
 risk, **S54**
 treatment, **S105–S106**
 hypogonadism, **S209**
 hypokalemia, **S165, S192, S194**
- inlisiran, **S7, S168–S169**
 incretin-based therapies, **S84, S181, S222–S224**
 Indian Diabetes Prevention Program (IDPP-1), **S44**
 infections, **S51, S62, S128, S144, S148, S207, S223, S273**
 diabetic foot, **S203–S204**
 influenza vaccines, **S53–S54, S55**
 inhaled insulin, **S117, S141, S143, S148, S153–S154**
 injection techniques, **S118, S142**
 insulin analogs, in type 1 diabetics, **S119, S140, S141, S144, S148, S149, S151, S152, S154, S224, S236, S270, S273**
 insulin delivery, **S112, S117**
 automated systems, **S118, S119**
 do-it-yourself closed-loop systems, **S120**
 injection techniques, **S118, S142**
 intravenous, transitioning to subcutaneous, **S270**
 pens and syringes, **S117–S118**
 pumps, **S118–S119**
 insulin pump therapy, **S118–S119**
 insulin resistance, **S5, S19, S20, S24, S25, S26, S27, S28, S29, S44, S45, S58, S59, S77, S86, S153, S245, S256, S257, S258, S259, S260, S261**
 insulin secretagogues, **S54, S72, S78, S105, S131, S222**
 insulin therapy
 access and affordability, **S279**
 dosing algorithms using machine learning, **S9, S268**
 in adults with type 1 diabetes, **S140–S142**
 in adults with type 2 diabetes, **S142–S154**
 basal, **S9, S113–S114, S116, S119, S140, S141, S150, S151, S152, S153, S154–S145, S222, S224, S226, S233, S269, S270, S271, S272, S273**
 combination injectable, **S154**
 concentrated insulins, **S152–S153**
 in hospitalized patients, **S269–S270**
 inhaled insulin, **S117, S141, S143, S148, S153–S154**
 monitoring for intensive regimens, **S113**
 in older adults, **S221–S224**
 prandial, **S7, S113, S141–S142, S143, S150, S151–S152, S154, S222, S233, S234, S243, S270, S271**
 insulin:carbohydrate ratio (ICR), **S144, S145**
 integrated CGM devices, **S6, S115**
 intensification, of therapy, **S141, S143, S149, S151, S154, S176**
 intermittent fasting, **S6, S73**
 intermittently scanned CGM devices, **S106, S114–S115, S116, S235, S236, S241, S258**
 International Association of the Diabetes and Pregnancy Study Groups (IADPSG), **S33–S36**
 International Diabetes Closed Loop (iDCL) trial, **S141**
 islet transplantation, **S32, S105, S142**
 isradipine, **S208**
- juvenile-onset diabetes. *see* immune-mediated diabetes.
- KDIGO study, **S194**
 ketoacidosis, diabetic, **S20, S60, S61, S77, S81, S106, S116, S141, S142, S148, S177, S224, S233, S243, S256, S260, S273**
 kidney disease. *see* chronic kidney disease
- Kumamoto study, **S101**
- language barriers, **S13**
 latent autoimmune diabetes in adults (LADA), **S20**
 Latino population, **S13**
 LEADER trial, **S174–S175, S180, S197**
 lifestyle behavior changes
 delivery and dissemination of, **S43**
 for diabetes prevention, **S42–S43**
 for hypertension, **S163**
 for lipid management, **S165–S166**
 for weight management, **S59, S71, S121**
 in older adults, **S220–S221**
 in pediatric type 1 diabetes, **S233–S234**
 in pediatric type 2 diabetes, **S7, S242**
 in pregnancy, **S9, S163**
 to reduce ASCVD risk factors, **S176**
 with NAFLD, **S6**
 linagliptin, **S148, S152, S173, S177, S182**
 lipase inhibitors, **S133**
 lipid management, **S165–S166, S225**
 lipid profiles, **S53, S166, S231, S232, S238, S239**
 liraglutide, **S44, S60, S132, S134, S142, S148, S151, S152, S153, S154, S174, S180, S182, S197, S243, S244**
 lispro, **S141, S153, S222**
 lixisenatide, **S148, S152, S153, S154, S174, S181, S182**
 long-acting insulin, **S141, S143, S145, S149, S150, S151, S153, S224, S234, S236, S242, S243, S254, S255, S262, S272, S273**
 Look AHEAD trial, **S60, S61, S130–S131, S176, S221**
 loss of protective sensation, **S8, S206, S209, S210**
 lovastatin, **S167**
- machine learning, dosing algorithms using, **S9, S268**
 macular edema, diabetic, **S204–S206**
 maternal history, in screening children/
 adolescents, **S25**
 maturity-onset diabetes of the young (MODY), **S19, S20, S30–S31, S230, S241**
 meal planning, **S6, S73–S75, S256**
 Medicaid expansion, **S13**
 medical devices, for weight loss, **S132**
 medical evaluation, **S5, S51–S62**
 autoimmune diseases, **S56**
 cancer, **S57–S58**
 cognitive impairment/dementia, **S57**
 immunizations, **S51, S53–S55**
 nonalcoholic fatty liver disease, **S57–S60**
 obstructive sleep apnea, **S60**
 periodontal disease, **S60**
 recommendations, **S48**
 medical nutrition therapy, **S69, S70–S76**
 alcohol, **S76**
 carbohydrates, **S73–S75**
 eating patterns and meal planning, **S73**
 fats, **S75**
 goals of, **S71**
 in hospitalized patients, **S271–S272**
 micronutrients and supplements, **S75–S76**
 nonnutritive sweeteners, **S76**
 protein, **S75**
 sodium, **S75**
 weight management, **S71**
 Mediterranean diet, **S42, S57, S59, S71, S72, S73, S74, S75, S166**

- meglitinides, S54, S152
 mental health referrals, S8, S54, S71, S79, S89, S81, S82, S83, S132, S234–S235, S246
 mental illness, serious, S81, **S84**
 metabolic surgery, S71, S81, S128, S129, S130, **S132–S136, S243–S244**
 metformin, S30, S31, S32, S43–S44, S53, S62, S75, S102, S103, S131, S142, S143, S146, S148, S149, S151, S152, S154, S173, S174, S176, S178, S182, S184, S196, S217, **S221, S222, S232, S242, S243, S245, S258, S259, S260, S261, S262, S273**
 metoclopramide, S209
 metoprolol, S208
 micronutrients, S71, S72, **S75–S76**
 microvascular complications, S11, S27, S31, S32, S45, **S78, S99, S101–S102, S104, S141, S142, S159, S206, S219, S239–S240, S255**
 midodrine, S208
 miglitol, S152
 migrant farmworkers, S13
 mineralocorticoid receptor antagonist therapy, S8, S164, S165, S183, S192, S193, S194, S196, **S198–S199**
 monogenic diabetes syndromes, S19, **S30–S32**
 multiple daily injections (MDI), S53, S113, S115, S116, S118, S119, S143, S144, S145, S243
 myasthenia gravis, S23, S56, S237
- naltrexone/bupropion ER, S132, S133
 nateglinide, S44, S152
 National Diabetes Data Group, S35
 National Diabetes Prevention Program, S43
 National Health and Nutrition Examination Survey (NHANES), S11, S21, S34, S241
 neonatal diabetes, S19, **S30**
 nephrologist, referral to, S8, S192, S193, S194, **S199**
 nephropathy, diabetic, S27, S165, S173, S175, S179, S197, S203, S209, S231, S232, S239, **S244, S256**
 neurocognitive function, **S217**
 neuropathic pain, S8, S208
 neuropathy, diabetic, S8, S44, S54, S101, S149, **S206–S209, S211, S231, S232, S240, S244, S256**
 - autonomic, S8, **S78, S160, S207, S273**
 - cardiac autonomic, S206, **S207**
 - gastrointestinal, **S207**
 - genitourinary disturbances due to, **S207**
 - peripheral, S56, **S78, S119, S206–S207, S210**
- new-onset diabetes after transplantation (NODAT), S29
 niacin + statin therapy, S169, **S170**
 nonalcoholic fatty liver disease (NAFLD), S6, S53, **S57–S60, S256**
 nonalcoholic steatohepatitis (NASH), S6, S57–S60, S148
 noninsulin treatments, S30, S106, S112, **S113–S114, S116, S142, S149, S152, S221, S222, S223, S258, S270**
 noninsulin-dependent diabetes. *see* type 2 diabetes.
 nonnutritive sweeteners, S72, **S76**
 NPH insulin, S141, S145, S148, S149, S150, S151, S152, S153, S155, S222, S224, S270, S272, S273
 nucleoside reverse transcriptase inhibitors, S22
 nursing homes, **S224–S225**
 nutrition
 - for diabetes prevention/delay, S42–S43
 - nutrition therapy. *see* medical nutrition therapy.
- obesity, S7, **S128–S139**
 - assessment, **S129**
 - medical devices for weight loss, **S132**
 - metabolic surgery, **S132, S135–S136**
 - nutrition, physical activity, and behavioral therapy, **S129–S131**
 - pharmacotherapy, **S131–S132, 133–134**
 - screening asymptomatic children/adolescents, S24, S25
- obstructive sleep apnea, S53, **S58, S86, S232, S245**
 ODYSSEY OUTCOMES trial, S168
 older adults, S7, **S216–S229**
 - end-of-life care, S225–S226
 - hypoglycemia, S217–S218
 - lifestyle management, S220–S221
 - neurocognitive function, S217
 - pharmacologic therapy, S221–S224
 - in skilled nursing facilities and nursing homes, S224–S225
 - treatment goals, S218–S220
 - with type 1 diabetes, S224
- one-step strategy, for GDM, S33–S34
 opioid antagonist/antidepressant combination, S133
 ophthalmologist, referral to, S78, S204, S205
 oral agents, S113, S114, S149, S151, S225, S259
 oral glucose tolerance test (OGTT), S20, S21, S25, S28, S29, S30, S31, S33, S34, S35, S258, S262
 organ transplantation, posttransplantation diabetes mellitus, S19, S29–S30
 orlistat, S132, S133
 orthostatic hypotension, **S208**
 overweight people, screening asymptomatic, S24 adults, S24
 children/adolescents, S24, S25
 oxygen, glucose monitors and, S114
 oxygen therapy
 - hyperbaric, S8, S211, S212
 - topical, S8, S209, S211, S212
- P2Y12 receptor antagonists, S170, **S172**
 palliative care, S219, S224, S225
 pancreas transplantation, **S142, S146**
 pancreatectomy, S32, S119
 pancreatic diabetes, S19, **S32**
 pancreatitis, S20, S32, S134, S148, S169, S181, S245
 pancreoprivic diabetes, S32
 pens, insulin, S112, **S117–S118**
 periodontal disease, S28, S54, **S60**
 perioperative care, S135, **S273**
 peripheral arterial disease, S210
 peripheral neuropathy, S56, **S78, S119, S206–S207, S210**
 pernicious anemia, S23, S56, S129
 person-centered care, S69, S101, S142, S143
 - collaborative care, S10, **S49–S51, S79**
 - goals, **S45–S46**
- pharmacologic approaches. *see also* specific medications, medication classes.
 - for adults with type 1 diabetes, **S140–S142**
 - for adults with type 2 diabetes, **S142–S154**
 - for cardiovascular and renal disease, S54, S176–S185, S196–S197
 - for hypertension, S163–S165
 - for lipid management, S166–S170
 - for neuropathic pain, S8, S208
 - for obesity, S131–S132
 - for pediatric type 2 diabetes, **S242–S243**
 - for smoking cessation, S79
 - in older adults, **S221–S224**
 - in pregnancy, **S259–S260**
 - in prediabetes, **S43–S44**
 - interfering substances for glucose meter readings, S114
 - to glycemic treatment, S7, S54, **S140–S157**
- phentermine, S44, S132, S133
 phentermine/topiramate ER, S132, S133, S244
 phosphodiesterase type 5 inhibitors, S209
 photocoagulation surgery, S205, S206
 physical activity, S10, S12, S15, S27, S28, S42, **S43, S50, S76–S78, S130–S131, S150, S176, S208, S221, S241, S242**
 - for depression, S83
 - for diabetes prevention, **S43**
 - glycemic control and, **S78, S106**
 - impact on blood glucose, S112, S113, S114, S119
 - in children with type 1 diabetes, **S233–S234**
 - in pregnancy, **S259**
 - with microvascular complications, **S78**
 - pre-exercise evaluation, **S78**
- pioglitazone, S5, S6, S44, S45, S59–S60, S148, S152
 PIONEER-6 trial, S174–S175, S180
 pitavastatin, S167
 Plenity, S132
 pneumococcal pneumonia vaccines, S6, **S54**
 point-of-care assays
 - A1c, S5, S21, S98
 - blood glucose monitoring, S269
- polycystic ovarian syndrome, S24, S25, S27, S232, **S245, S256, S258, S259**
 population health, S5, **S10–S18**
 - care delivery systems, S11
 - care teams, S12
 - chronic care model, S11
 - recommendations, S10
 - social context, S13–S15
- postbariatric hypoglycemia, S132, S136
 postpancreatitis diabetes mellitus (PPDM), S32
 postpartum care, in diabetic women, **S261–S262**
 postpartum state, A1C in, S22
 posttransplantation diabetes mellitus, S19, **S29–S30**
 pramlintide, S142, S152, S209
 prandial insulin, S7, S113, S141–S142, S143, S150, **S151–S152, S154, S222, S233, S234, S243, S270, S271**
 pravastatin, S167
 prediabetes, **S24–S25**
 - criteria defining, S25
 - diagnosis, S25
 - prevention of vascular disease and mortality, **S44–S45**
 - screening, S5, S24–S25
- preeclampsia, in women with diabetes, S33, S34, S163, S254, S255, S257, S258, S259
 aspirin and, S260–S261
 pregabalin, S132, S208
 pregnancy, S8, S9, S19, **S254–S266**
 - A1C and, S21, S22, S257–S258
 - continuous glucose monitoring in, S258
 - diabetes in, S254–S255
 - drug considerations in, **S261**
 - eye exams during, S255

- gestational diabetes mellitus (GDM), S9, S19, S24, S25, S27, **S32–S35**, S43, S44, S254, **S258–S260**, **S261–S262**
- glucose monitoring in, S257
- glycemic targets in, **S256–S258**
- insulin physiology in, S257
- metformin in, S259
- pharmacologic therapy, S259
- physical activity in, S259
- postpartum care, **S261–S262**
- pre-existing type 1 and 2 diabetes in, S255, S256, S257, **S260**
- preconception care, **S255**, **S256**
- preconception counseling, **S254–S255**
- preeclampsia and aspirin, **S260–S261**
- real-time CGM device use in, **S116**
- retinopathy during, **S204–S205**
- sulfonylureas, S259
- prevention, type 2 diabetes, S5, S8, **S41–S48**
- lifestyle behavior change, **S42–S43**
- person-centered care goals, **S45–S46**
- pharmacologic interventions, **S43–S44**
- recommendations, S41, S42, S43–S44
- of vascular disease and mortality, **S44–S45**
- proliferative diabetic retinopathy, S78, S204, S205
- proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, S7, S166, S167, **S168**, S170
- protease inhibitors, A1C and, S22
- protein intake, **S75**, S193, S195, S220, S244
- psychosocial care, S6, S51, **S79–S86**
- anxiety disorders, S82
- cognitive capacity/impairment, S84–S86
- depression, S82–S83
- diabetes distress, S81–S82
- disordered eating behavior, S83–S84
- in pediatric type 1 diabetes, S234–S235
- in pediatric type 2 diabetes, S246
- in pregnancy, S261
- referral to mental health specialist, S80–S81
- serious mental illness, S86
- sleep health, S86
- pumps, insulin, S112, S117, **S118–S120**
- do-it-yourself closed-loop system, S120
- in type 2 and other types of diabetes, S119
- in youth, S119
- sensor augmented, S119
- quality improvement, S5, S13, S267, S270
- RAAS inhibitors, S195, **S196**
- Race, S24, S25, S70, S105, S118, S131, S159, S173, S174, S178, S193
- effect on A1C, S21, S22
- rapid-acting insulin analog, S105, S118, S119, S140, S141, S143, S145, S150, S152, S153, S222, S225, S258, S271, S272, S273
- real-time CGM devices, S7, S106, S114–S115, S116, S136, S235, S236, S241, S256, S258, S269
- REDUCE-IT trial, S75, S169
- referrals, S58, S70, S260
- for cognitive testing, S84, S219
- for community screening, S28
- for comprehensive eye exam, S204, S240, S245, S255
- for local community resources, S13
- for DSME, S54, S70, S217
- for tobacco cessation, S44
- from dentist to primary care, S28
- to behavioral health provider, S217
- to foot care specialist, S8, S211
- to gastroenterologist, S245
- to mental health professional, S8, S80–S81
- to nephrologist, S8, S192, S194, **S199**, S244
- to neurologist, S206, S231
- to sleep specialist, S87, S245
- to registered dietitian nutritionist, S43, S255, S257, S274
- registered dietitian nutritionist (RDN), S43, S255, S257, S274
- reimbursement, for DSMES, S69, **S70**
- repaglinide, S29, S152
- retinopathy, diabetic, S8, S27, S54, S58, S77, **S78**, S101, S119, S161, S193, S194, S198, **S203–S206**, S209, S231, S232, S237, S240, S244–S245, S255, S256, S260
- REWIND trial, S175, S181
- risk calculator, for ASCVD, S6, **S159**
- risk management
- cardiovascular disease, S7, **S158–S190**
- chronic kidney disease, S8, **S191–S202**
- risk, screening for, S23–S28
- rivaroxaban, S170, S172
- rosiglitazone, S148
- Roux-en-Y gastric bypass, S135
- SAVOR-TIMI trial, S173, S182
- saxagliptin, S148, S152, S173, S182, S270
- schizophrenia, S84
- schools
- device use in, **S112**
- diabetes care in, **S234**
- pediatric type 1 diabetes and, S233
- screening
- for cardiovascular disease, **S159–S160**
- in children/adolescents, S28
- community, S28
- in dental practices, S28
- for gestational diabetes mellitus, S28, **S32–S33**
- in individuals with HIV, S28
- medications, S28
- for neuropathy, S240
- for prediabetes and type 2 diabetes, S27–S28
- testing interval, S28
- for type 1 diabetes, S23–S24
- for type 2 diabetes, **S240–S241**
- seasonal farmworkers, S13
- self-monitoring of blood glucose (SMBG). *see* blood glucose monitoring (BGM)
- semaglutide, S44, S60, S132, S134, S146, S148, S149, S151, S152, S174–S175, S180–S181, S182, S197, S222
- sensor-augmented pumps, S8, S106, S118, **S119**, S141, S144, S218, S236, S260
- sensory impairment, S53, S209, S210
- setmelanotide, S132
- sexual dysfunction, S207
- sickle cell disease, A1C and, S21, S22
- simvastatin, S167, S168, S170
- sitagliptin, S148, S152, S173, S182
- skilled nursing facilities, S223, **S224–S225**
- sleep health, S86
- smart pens. *see* connected insulin pens
- smoking cessation, S45, S51, **S79**, S239
- social capital, S15
- social context, S13–S15
- social determinants of health (SDOH), S7, S11–S13, S15, S70, S80, S147
- sodium intake, S72, S74, **S75–S76**, S163
- sodium–glucose cotransporter 2 (SGLT2) inhibitors, S102, S103, S142, S148, S149, S151, S152, S154, S158, S159, **S177–S180**, S181, S182, S183, S184, S194, S196, S197, S198, S218, **S224**, S270, S273
- SOLOIST-WHF trial, S183
- sotagliflozin, S180, S182, S183
- SPRINT trial, S160, S161, S162
- staging
- of diabetic kidney disease, S54, **S194**
- of type 1 diabetes, S20
- statin therapy, S5, S7, S44, S45, S75, **S166–S169**, S173, S174, S176, S178, S220, S231, S232, S238, S239, S245
- diabetes risk with, **S170**
- with bempedoic acid, **S169**
- with fibrates, S169, **S170**
- with niacin, S169, **S170**
- statins, **S57**
- sulfonylureas, S8, S14, S30, S31, S99, S146, S148, S152, S154, S221, S222, S224, **S259**
- supplements, dietary, S72, **S75–S76**, S130, S131
- surveillance
- for foot problems, S209–S211
- of chronic kidney disease, S194–S195
- SUSTAIN-6 trial, S174–S175, S180, S197
- sweeteners, nonnutritive, S72, **S76**
- sympathomimetic amine anorectics, S133
- in combination with antiepileptic, S133
- syringes, insulin, S117–S118
- tapentadol, S208
- technology, diabetes, S6, S12, **S111–S127**
- blood glucose monitoring, **S112–S114**
- continuous glucose monitoring devices, **S114–S117**
- general device principles, **S111–S112**
- insulin delivery, **S117–S121**
- TECOS trial, S173, S182
- TEDDY study, S24
- telehealth, S11
- temperature
- of glucose monitor, S114
- perception of, S206, S209, S210
- testing interval, S28
- testosterone, low, in men, S44
- tetanus, diphtheria, pertussis (TDAP) vaccine, S55
- thiazide-like diuretics, S164, S165, S196
- thiazolidinediones, S30, S44, S131, S148, S183, **S222**
- thyroid disease
- autoimmune, S31, S56
- in pediatric type 1 diabetes, S231, **S237**
- time-restricted eating, S6, S73
- tirzepatide, S7, S44, S60, S131, S146, S152
- tobacco cessation, S44, S68, **S79**, S239, S246
- training
- blood glucose awareness, S82
- on device use, S112
- tramadol, S208
- transfusion, A1C and, S21
- transition
- from hospital to ambulatory setting, S270, **S273–S274**
- from pediatric to adult care, S230, **S246**
- transplantation
- islet, S105, **S142**, S146

- liver, S58
- organ, post-transplant diabetes mellitus after, S19, S29–S30
- pancreas, **S142**, S146
- renal, S146, S57, S173, S174, S180, S182, S197
- tricyclic antidepressants, S8, S131, S207, **S208**, S209
- TWILIGHT trial, S172
- two-hour plasma glucose (2-h PG) test, S20, S21, S22, S25, S31, S33, S34
- two-step strategy, for GDM, S34–S335
- type 1 diabetes, S8, S9, S12, S13
 - A1C and cardiovascular disease outcomes in, S103
 - beta-cell replacement therapy, S142, S146, S175
 - in children/adolescents, **S233–S240**
 - classification, **S19–S20**
 - diagnosis, **S22–S24**
 - idiopathic, S23
 - immune-mediated, S23
 - in hospitalized patients, S270
 - insulin therapy, **S140–S142**
 - noninsulin treatments, **S142**
 - in older adults, S8, S224
 - peripheral neuropathy in, S206
 - pregnancy in women with preexisting, S9, S205, S255, S257, S258, **S260**
 - retinopathy in, S8, 204
 - screening, S23–S24
 - staging, S20
- subcutaneous insulin regimens, S112, S114–S115, S140, S144–S145, S148
- surgical treatment, **S142**
- type 2 diabetes
 - A1C and cardiovascular disease outcomes in, S103
 - in children/adolescents, **S240–S246**
 - classification, **S19–S20**
 - combination therapy, S7, S143, S144, S146, S147, S149, S150–S151, S154, S161, S168, S168–S169, S169–S170, S208, S222
 - initial therapy, S119, S238
 - insulin pump use in, S119
 - obesity and weight management, S6, S27, S59, S60, S120, **S128–S136**, S244
 - pharmacologic treatment in adults, **S142–S154**
 - pregnancy in women with preexisting, **S260**
 - prevention or delay, **S41–S48**
 - retinopathy in, S204
 - risk test for, S26
 - screening in asymptomatic adults, S27–S28
 - screening in children/adolescents, S4, S28
- type 3c diabetes, S32
- UK Prospective Diabetes Study (UKPDS), S101, S102, S103, S104, S176
- ulcers, foot, S53, S78, S206, **S209–S212**
- ultra-rapid-acting insulin analogs, S143, S145
- vagus nerve stimulator, S132
- vascular disease, S176, S209
- prevention of, in prediabetes, **S44–S45**
- VERIFY trial, S149
- vertical sleeve gastrectomy, S135
- VERTIS CV trial, S178, S179, S180
- Veterans Affairs Diabetes Trial (VADT), S101, S102, S103, S218
- vildagliptin, S149
- vitamin D supplementation, S44, S72, S76, S131
- VOYAGER-PAD trial, S172
- weight loss surgery. *see* metabolic surgery.
- weight loss/management, **S70–S76**, S163, S165, S176, S208, S220–S221
 - in diabetes prevention, S6, S9, S28, S29, S42–S43, S44, S45, S76
 - in type 1 diabetes, S20
 - in type 2 diabetes, S6, S27, S59, S60, S120, **S128–S136**, S244
- well-being, S6, S12, **S68–S97**, **S236**
- whites, non-Hispanic, S22, S25, S28, S61, S77, S98, S160, S173, S174, S178
- WISDM trial, S8, S218
- zoster vaccine, S55